These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.